Evidence map›Paper›PMID 29686149›Full record

ArticleAntimicrobial agents and chemotherapy2018

Retained Activity of an O25b-Specific Monoclonal Antibody against an Mcr-1-Producing Escherichia coli Sequence Type 131 Strain.

Luis M Guachalla, Katharina Ramoni, Cecilia Varga, Michele Mutti, Akela Ghazawi, Tibor Pál, Eszter Nagy, Ágnes Sonnevend, Gábor Nagy, Valéria Szijártó

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Global epidemiology, genetic environment, risk factors and therapeutic prospects ofFrontiers in cellular and infection microbiology · 2022
    Review
  2. Strategies to Tackle Antimicrobial Resistance: The Example ofInternational journal of molecular sciences · 2021
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Luis M GuachallaArsanis Biosciences, Vienna, Austria.
Katharina RamoniArsanis Biosciences, Vienna, Austria.
Cecilia VargaArsanis Biosciences, Vienna, Austria.
Michele MuttiArsanis Biosciences, Vienna, Austria.
Akela GhazawiCollege of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
Tibor PálCollege of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
Eszter NagyArsanis Biosciences, Vienna, Austria.
Ágnes SonnevendCollege of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
Gábor NagyArsanis Biosciences, Vienna, Austria.
Valéria SzijártóArsanis Biosciences, Vienna, Austria valeria.szijarto@arsanis.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plasmid-encoded colistin resistance is emerging among extraintestinal pathogenic

Indexed as

AnimalsAnti-Bacterial AgentsAntibodies, MonoclonalColistinDrug Resistance, Multiple, BacterialEndotoxinsEscherichia coli InfectionsEscherichia coli ProteinsExtraintestinal Pathogenic Escherichia coliFemaleHumansLipopolysaccharidesMiceMice, Inbred BALB CAnti-Bacterial AgentsAntibodies, MonoclonalColistinEndotoxinsEscherichia coli ProteinsLipopolysaccharidesMCR-1 protein, E coliEscherichia coli ST131mcr-1monoclonal antibodies

Identifiers

PMID29686149
PMCPMC6021686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.